Outstanding financial performance and strong progress on delivery of strategy
NZX/ASX Market Release
Overview for the year ended 30 June 2018 (NZ$)
- Total revenue of $922.7 million – an increase of 68% over the prior corresponding period (pcp)
- EBITDA[1] of $283.0 million – up 101% on pcp
- Net profit after tax of $195.7 million – 116% ahead of the pcp
- Strong cash conversion with operating cash flow of $231.1 million – up 131% on pcp
- EBITDA to sales margin of 31% – up from 26% in the pcp
- Basic earnings per share (EPS) of 27.0 cents – up from 12.7 cents in the pcp
- Infant formula share strengthening to 5.1% in China[2] and 32% in Australia[3]
- Substantial physical distribution growth to ~10,000 stores in China and ~6,000 stores in the US
- Enhanced strategic partnerships with Synlait and Fonterra
To view the FY18 Annual Report, please click here
To view the FY18 Annual Report (single page for printing), please click here
To view the FY18 Annual Report presentation, please click here
To view the NZX Appendix 1 FY18, please click here
To view the full year results commentary FY18, please click here
To view the ASX Appendix 4G FY18, please click here
To view the ASX Appendix 4E FY18, please click here
[1] Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non GAAP measure. However, the Company believes that it assists in providing investors with a comprehensive understanding of the underlying performance of the business. A reconciliation of EBITDA to net profit after tax is shown at the end of this document [2] Kantar Infant Formula market tracking of Tier 1 and Key A cities for 12 months ending June 2018 by value (Kantar track a substantial proportion of the total market) [3] Aztec Australian Grocery and Pharmacy Scan value share 12 months ending 30/06/18
